Currently, several protein kinase-modulating compounds have received market approval across a range of diverse therapeutic indications. Furthermore, a large number of chemical and biological protein kinase-modulating compounds are undergoing testing at the preclinical and clinical level. Protein kinases are both major pharmacological targets and diagnostically useful. Progression of kinase modulators toward clinically viable therapies is aided by a reversible mechanism of action, short treatment durations and patient-compliant administration routes. However, the physiological role and essential functional activity of protein kinases in many organs and tissues complicates, to different extents, the development of useful, highly potent protein kinase modulators. In this review, we will highlight common problems in the development of these compounds and lessons learned from the extensive preclinical and clinical characterization of some key protein kinase modulators, some of which have either entered and successfully completed clinical trials or have been abandoned as a consequence of unacceptable toxicity issues. We will ultimately explore how molecular profiling tools combined with histopathological endpoints can be adopted to address and further understand these toxicities in humans and understand their relevance and characterization when identified during early animal experiments.
Assessing and managing toxicities induced by kinase inhibitors / R.E. Castoldi, G. Pennella, S.G. Saturno, P. Grossi, M. Brughera, M. Venturi. - In: CURRENT OPINION IN DRUG DISCOVERY & DEVELOPMENT. - ISSN 1367-6733. - 10:1(2007 Jan), pp. 53-57.
|Titolo:||Assessing and managing toxicities induced by kinase inhibitors|
CASTOLDI, RAFFAELLA ERICA (Primo)
|Parole Chiave:||biomarker ; preclinical development ; protein kinase ; tissue damage ; toxicology|
|Data di pubblicazione:||gen-2007|
|Appare nelle tipologie:||01 - Articolo su periodico|